No Data
Debon Securities: The third quarter of 2024 may mark the bottom of chemical profits, with a turning point in the capacity cycle.
In the third quarter, the industry gross margin was 16.22%, -0.35pct year-on-year, -1.12pct quarter-on-quarter; net income attributable to mother was 5.01%, -0.34% year-on-year, -1.29pct quarter-on-quarter.
Zhejiang Medicine Co., Ltd. (SHSE:600216) Might Not Be As Mispriced As It Looks
Zhejiang Medicine Q3 Profit Surges 1,738%, Revenue Climbs 40%
Zhejiang Pharmaceutical Report for the Third Quarter of 2024
Zhejiang Medicine (600216.SH) released its performance for the first three quarters, with a net income of 0.85 billion yuan, a year-on-year increase of 181.96%.
zhejiang medicine (600216.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Sinolink: BASF's VE production delay, still bullish on the price of vitamin products.
With the delay in the resumption of production at BASF, the time for overseas supply to contract in stages will also be extended.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past WeekNo Data
No Data
